
Beyond efficacy: What tolerability should mean in GLP-1 RA based development
Bo Liang, Chief Medical Officer, and Roman Cailleteau, Head of Clinical Development-Metabolic at CORXEL Pharmaceuticals, explore why tolerability for GLP-1 therapies is essential. When new GLP-1 receptor agonists (RA) clinical data are released, one endpoint tends to catch all attention: percentage of weight loss. While efficacy paired… Read More













